Union for International Cancer Control

Printer-friendly version
144th session of the Executive Board<br>24 January - 1 February 2019
Agenda Item: 
5.7.2 Cancer medicines

Thank you for the opportunity to deliver this statement on behalf of the UICC, representing over 1,000 member organisations across 170 countries and territories, supported by the NCD Alliance.

We warmly welcome the report and applaud the secretariat on its thorough examination of the issues. The timing of the report is auspicious as cancer is now the second leading cause of mortality globally. There were 18.1m cancer cases in 2018 and 9.6m cancer deaths, and we expect this to increase to 29.5m new cases annually by 2040. Many of these deaths could be averted if cancer patients had access to timely diagnosis and treatment.

Recognising the potential for action, we encourage Member States to integrate cancer in sustainable universal health coverage plans. Using the options contained in the report, countries can improve pricing and procurement strategies for cancer medicines and other health products, recognising access is a pillar for strong health systems. Many NGOs are currently supporting cancer patients and we encourage Member States to engage them as a key partner in taking these actions forward.

We call on WHO to use the findings in this report and integrate them within technical guidance to best support Member States. Leveraging the disease-based approach of oncology section in the WHO model list of essential medicines (EML), the prequalification programme and the clear pricing policy options contained in the report that call for increased transparency on medicine prices, WHO can support Member States to improve access to cancer medicines as part of the journey to achieve the Sustainable Development Goals. As a contributor to the update of the EML, UICC would have welcomed the opportunity to input into the report and stands ready to input into future such reviews.

We welcome the opportunity to support WHO and Member States in their endeavour to improve access and affordability for 18,1 million cancer patients worldwide.